Company intelligence / Profile preview

Orbona Pharma

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Orbona Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine and metabolic diseases. The company's lead program, ORB-101, is a potent and selective small molecule inhibitor of 11β-hydroxylase (CYP11B1) currently being evaluated for the treatment of Congenital Adrenal Hyperplasia (CAH). By targeting the steroidogenic pathway, Orbona aims to provide better hormonal control and reduce the reliance on high-dose glucocorticoids in patients with CAH. The company is led by an experienced management team with deep expertise in endocrinology and orphan drug development.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Orbona Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbona Pharma.

Explore the full profile